摘要
嵌合抗原受体(CAR)-T细胞疗法是一种利用基因工程技术改造患者的T细胞,使其表达特定的嵌合抗原受体,从而特异性地识别并杀伤携带目标抗原的肿瘤细胞或靶细胞的免疫治疗方法。该治疗方法在系统性红斑狼疮、抗合成酶综合征、寻常型天疱疮等自身免疫性疾病的应用中取得了令人鼓舞的疗效,但也面临着安全性、成本效益和治疗时机选择等多方面的挑战。
Chimeric antigen receptor(CAR)T cell therapy is a type of immunotherapy that utilizes genetic engineering to modify a patient's T cells to express specific CARs,thereby enabling them to specifically recognize and eliminate tumor cells or target cells carryinging the target antigen. This therapeutic approach has shown encouraging results in autoimmune diseases such as systemic lupus erythematosus,antisynthetase syndrome,and pemphigus vulgaris;however,it also faces challenges in terms of safety,cost-effectiveness,and timing of treatment.
作者
邹波
杨娉婷
ZOU Bo;YANG Ping-ting(Department of Rheumatology and Immunology,the First Hospital of China Medical University,Shenyang I10001,China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2024年第6期466-471,477,共7页
Chinese Journal of Practical Internal Medicine
基金
沈阳市科技计划项目(公共卫生研发专项)(22-321-31-01)。
作者简介
通信作者:杨娉婷,电子信箱:yangpingtingting@163.com。
